| To: The Devil Dog who wrote (68) | 3/31/2000 12:36:00 PM | | From: Gary H | | | |
Short clip in the National Post states;
"Lorus was one biotech that bucked the trend, rising .26 to $4.65 after announcing that a study of it's leading anti-cancer drug showed "excellent" anti-tumor activity." |
| | Lorus Therapeutics LORFF LOR | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Gary H who wrote (69) | 4/1/2000 8:44:00 PM | | From: Salt'n'Peppa | | | |
Stockhouse discovers time travel!
It's true.
The home page on Stockhouse features an article on Biomira and their cancer research.
The article is interesting, but it is dated April 3rd!
stockhouse.com
This must be their idea of an April fools joke.
Regardless, it hints at renewed interest in the biotech sector, which is of interest to LOR. |
| | Lorus Therapeutics LORFF LOR | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: LaFayette555 who wrote (72) | 4/20/2000 9:42:00 AM | | From: Claude Robitaille | | | |
Lorus enters agreement for $25-million bought deal
Lorus Therapeutics Inc LOR
Shares issued 78,751,668 Apr 19 close $3.30
Thu 20 Apr 2000 News Release
Mr. Philippe Lacaille reports
Lorus Therapeutics has entered into an agreement with a syndicate of
underwriters to issue and sell 8,333,334 common shares of Lorus
Therapeutics Inc. at a price of $3 per common share for gross proceeds of
$25-million through a bought deal. The agreement includes an option for the
underwriters to increase the issue to 13,333,334 common shares
($40-million) prior to filing the final short form prospectus and an
overallotment option of 15 per cent of the final issue size exercisable for
a 30-day period from the closing of the offering. The deal is expected to
close on or about May 2, 2000.
The syndicate is being led by HSBC Securities (Canada) Inc. and includes
Yorkton Securities Inc., TD Securities Inc. and Dominick & Dominick
Securities Inc. The transaction is subject to the receipt of all necessary
regulatory and stock exchange approvals and to the execution of definitive
documentation. As previously announced, Lorus filed a preliminary short
form prospectus with the securities commissions and similar regulatory
authorities in all Canadian provinces to qualify the issuance of the common
shares.
The proceeds provide the company with the resources to accelerate the
development of its antisense and small molecule anticancer drugs, to build
increased value in Virulizin through a pivotal phase III trial, and to
support corporate development initiatives.
"A financing at this time was the next logical step in our strategy of
building critical mass," said Philippe G. Lacaille, chairman and chief
executive officer of Lorus Therapeutics Inc. "Increased interest in the
biotech sector combined with Lorus's strong fundamentals has provided a
unique window of opportunity and enabled the company to achieve this
significant milestone. This financing allows Lorus to accelerate the
development of its diverse pipeline of novel oncology drugs."
WARNING: The company relies upon litigation protection for
"forward-looking" statements.
(c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com |
| | Lorus Therapeutics LORFF LOR | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Claude Robitaille who wrote (73) | 4/24/2000 11:09:00 PM | | From: Claude Robitaille | | | |
Lorus Files Final Prospectus for $40 Million Bought Deal
TORONTO--(BUSINESS WIRE)--April 24, 2000--Lorus Therapeutics Inc. (``Lorus'') today announced that it has filed a final short form prospectus in respect of a previously announced bought deal. The size of the offering is 13,333,334 Common Shares at a price per share of $3.00 for gross proceeds of $40 million. Lorus has granted the underwriters an option to purchase up to 2,000,000 additional Common Shares at $3.00 per share to cover over-allotments and for market stabilization purposes, which may be exercised for a 30 day period after closing of the offering. Closing is expected on or about May 2, 2000. The syndicate of underwriters is being led by HSBC Securities (Canada) Inc. and includes Yorkton Securities Inc., TD Securities Inc. and Dominick & Dominick Securities Inc.
The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state in which such an offer, solicitation or sale would be unlawful.
Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical development and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the NASDAQ OTC BB exchange under the symbol LORFF.
Except for historical information, this press release contains forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual reports and 20-F filings.
Lorus Therapeutics Inc.'s press releases are available through the Company's Internet site: www.lorusthera.com.
--------------------------------------------------------------------------------
Contact:
Investor Relations Exchange
Mimi Choi, 416/599-6152 (IR)
Fax: 416/599-8429
mchoi@mcipr.com or ir@lorusthera.com
or
Mansfield Communications Inc.
Julija Hunter or Pereina Choudhury, 416/599-0024 (MR)
Fax: 416/599-7484
jhunter@mcipr.com or pchoudhury@mcipr.com |
| | Lorus Therapeutics LORFF LOR | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Claude Robitaille who wrote (74) | 4/25/2000 7:59:00 AM | | From: Claude Robitaille | | | |
Lorus Therapeutics included in TSE 300
Lorus Therapeutics Inc LOR
Shares issued 78,751,668 Apr 24 close $3.33
Tue 25 Apr 2000 News Release
Ms. Mimi Choi reports
Lorus Therapeutics was added by Standard & Poors to the TSE 300 Composite
Index after the market close on April 19, 2000.
The TSE 300 Composite Index (TSE 300), introduced in 1977, was created by
The Toronto Stock Exchange and is maintained by Standard & Poors. It is
composed of the 300 largest Canadian public companies on the TSE and is
regarded as a barometer of activity in the Canadian markets. Standard &
Poors reviews and follows strict criteria regarding inclusion and makes
adjustments accordingly.
"We are very proud to be part of this select group of Canadian public
companies," said Philippe G. Lacaille, chairman and chief executive officer
of Lorus Therapeutics Inc. "The TSE 300 is the standard bearer of the
Canadian stock market. We would like to take this opportunity to thank our
shareholders for their support of our research and development of
innovative cancer therapies."
Standard & Poors, in consultation with The Toronto Stock Exchange, reserves
the right to include or exclude any stock within the TSE 300 composite
index as it may in its sole and absolute discretion determine. The criteria
for inclusion are continually reviewed with the advice of, and in
consultation with, the index committee, and may be subject to change at any
time.
WARNING: The company relies on litigation protection for "forward-looking"
statements.
(c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com |
| | Lorus Therapeutics LORFF LOR | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Claude Robitaille who wrote (75) | 5/19/2000 12:02:00 AM | | From: Claude Robitaille | | | |
Lorus selects NC 381 for clinical development
Lorus Therapeutics Inc LOR
Shares issued 78,751,668 May 17 close $2.49
Thu 18 May 2000 News Release
Ms. Mimi Choi reports
Lorus Therapeutics, through its 80-per-cent-owned subsidiary, NuChem
Pharmaceuticals Inc., has chosen NC 381 as its lead anticancer drug for
further studies in preparation for clinical trials.
From a library of several hundred compounds investigated at the Harvard
Medical School and in-licensed to Lorus through its subsidiary, three
potential lead anticancer compounds were chosen for further detailed
investigations to determine the most effective anticancer compound in
preclinical studies including animal tumour models.
In studies with more than 300 mice containing different tumours, NC 381
treatment was found to significantly reduce the growth of a variety of
cancers, including tumours derived from human large cell lung carcinoma,
human pancreatic carcinoma, human kidney carcinoma and mouse fibrosarcoma.
NC 381 also significantly inhibited the metastasis of malignant melanoma
cells (that is the spread of tumour cells to other organs in the body).
"Death from cancer is usually due to the spread (metastasis) of cancer
cells from the primary or original site to other organs in the body, so it
is vital that we develop new drugs that have antimetastatic properties like
those found with NC 381," said Philippe G. Lacaille, chairman and chief
executive officer of Lorus Therapeutics Inc. "The finding that NC 381 can
be taken orally, for example, in pill form, is significant because it means
the drug can enter the body in a less invasive way than most
chemotherapeutic drugs and potentially improve the quality of life for
patients."
Preliminary toxicology studies have shown a very good safety profile for NC
381. Formal preclinical toxicology studies will begin in June, 2000, and it
is anticipated that an investigational new drug (IND) application will be
submitted for clinical trial approval by early next year.
NC 381 was originally designed as an analog or chemical variation of a
well-known antifungal agent, clotrimazole. In past studies, the drug
revealed an unique dual mode of antitumour action, stopping cancer cells
from dividing (antiproliferative) as well as preventing the formation of
blood vessels (antiangiogenic) required for tumour development.
WARNING: The company relies on litigation protection for "forward-looking"
statements.
(c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com |
| | Lorus Therapeutics LORFF LOR | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Claude Robitaille who wrote (76) | 6/13/2000 7:49:00 AM | | From: Claude Robitaille | | | |
Lorus patent allowed by U.S. Patent Office
Lorus Therapeutics Inc LOR
Shares issued 120,945,940 Jun 12 close $3.30
Tue 13 Jun 2000 News Release
Mr. Philippe Lacaille reports
A patent was allowed by the United States Patent and Trademark Office to
specifically protect GTI-2501, one of Lorus's lead anticancer drugs.
The patent ("Antitumour Antisense Sequences Directed Against R1 and R2
Components of Ribonucleotide Reductase") was allowed based on the unique
antitumour activity of GTI-2501, which is directly related to the positive
findings of tumour regression in mouse models with human tumours derived
from breast and kidney cancers.
The allowed patent gives Lorus strong protection for the unique composition
of GTI-2501, safeguards Lorus's interests in the anticancer drug GTI-2040,
which is currently in a Phase I/II clinical trial, and insulates Lorus'
technology on the design and use of unique antisense, anticancer drugs that
target the expression of two genes that play critical roles in the
development of cancer.
"This patent acknowledges the outstanding activity of GTI-2501, which
entered into toxicity studies earlier this month. The toxicity studies are
expected to be completed by the end of the year and represent the
achievement of another company milestone," said Philippe G. Lacaille, chair
and chief executive officer. "Upon completion of the toxicity studies, we
expect to file an investigational new drug (IND) submission with the Food
and Drug Administration and then proceed to clinical trials."
Lorus is a biopharmaceutical company focused on the research and
development of cancer therapies. Lorus' goal is to capitalize on its
research, pre-clinical, clinical and regulatory expertise by developing new
drug candidates that can be used, either alone, or in combination, to
successfully manage cancer. Through an active acquisition and in-licensing
program, Lorus is building a portfolio of promising anticancer drugs.
Late-stage clinical developments and marketing will be done in cooperation
with strategic pharmaceutical partners. Founded in 1986, Lorus is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on
the NASDAQ OTC BB exchange under the symbol LORFF.
(c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com |
| | Lorus Therapeutics LORFF LOR | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Claude Robitaille who wrote (77) | 6/26/2000 9:20:00 AM | | From: Claude Robitaille | | | |
Lorus moving into pivotal phase three trials
Lorus Therapeutics Inc LOR
Shares issued 120,945,940 Jun 23 close $3.15
Mon 26 Jun 2000 News Release
Ms. Jody Bullen reports
Lorus Therapeutics has completed meta-analysis of three phase one and two
studies of Virulizin. The studies showed that the drug demonstrated
clinical activity (such as increasing survival rate and preserving quality
of life) and was well tolerated by patients. Based on these encouraging
findings, Lorus plans to file an investigational new drug application (IND)
later in the year in preparation for a pivotal phase three clinical trial.
Dr. Benny Zee, senior biostatistician at the National Cancer Institute of
Canada, conducted the meta-analysis of results obtained with patients with
advanced pancreatic cancer and found that the number of adverse effects of
Virulizin were low for all three studies. He also found that the survival
results of Virulizin were superior to those found in a comparable study
using gemcitabine, the standard anticancer treatment for pancreatic cancer,
and as well as other benchmark findings.
"In the most conservative estimate of survival, the results of the
Virulizin study were better than a similar patient population receiving
gemcitabine in a phase two study setting as reported by Rothenberg in
1996," said Mr. Zee. "The survival experience of the Virulizin patients was
also significantly better than that of the 5-FU arm of the Burris phase
three study (1997) with respect to nine-month survival rates."
"By pursuing phase three trials independently for Virulizin, Lorus will
provide shareholders with the greatest value as the product is moved closer
to market. Lorus is well positioned to move forward with Virulizin, we have
the results, resources, knowledge and infrastructure to proceed," said
Philippe G. Lacaille, chairman and chief executive officer of Lorus. "
Virulizin's meta-analysis results combined with the evidence obtained from
previous studies have led to our decision to begin a phase three clinical
trial for Virulizin, confirming our belief that it will be an effective
therapy and important treatment of pancreatic cancer in the future."
Sixty-one patients were included in this analysis, with 49 classified as
evaluable. The majority of these patients (87 per cent) had received some
form of treatment prior to entering these studies: 46 per cent receiving
gemcitabine, 5-FU or other chemotherapeutic agents and 84 per cent had
prior surgery. There was no difference in survival between patients who had
or had no prior chemotherapy, but those who did not receive prior surgery
had worse prognosis as compared to those who had prior surgery.
Among the 61 eligible patients treated with Virulizin, the median survival
rate was 4.6 months. The six-month survival rate was 38 per cent and the
nine-month survival rate was 25 per cent. In terms of evaluable patients
(49 patients) the median survival rate was 5.7 months (95 per cent C.I.
from 4.6 months to 8.0 months) with six-month and nine-month survival rates
of 48 per cent and 31 per cent, respectively.
This result is better when compared with that of 63 patients who received
gemcitabine as second line therapy after they had failed 5-FU as
chemotherapy (Rothenberg et al.). The median survival in the Rothenberg
study was approximately 3.8 months, with a six-month survival rate of 31
per cent and a nine-month survival of 15 per cent.
(c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com |
| | Lorus Therapeutics LORFF LOR | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
